X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2884) 2884
Publication (192) 192
Book Review (35) 35
Book Chapter (7) 7
Magazine Article (5) 5
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2389) 2389
index medicus (1638) 1638
pyridones - administration & dosage (1449) 1449
male (1375) 1375
pyridones - therapeutic use (1237) 1237
female (1171) 1171
administration, oral (904) 904
animals (762) 762
pyridones - adverse effects (699) 699
middle aged (690) 690
pyridones - pharmacology (676) 676
aged (664) 664
adult (580) 580
treatment outcome (528) 528
rivaroxaban (516) 516
pyrazoles - administration & dosage (500) 500
dabigatran (494) 494
pyrazoles - therapeutic use (459) 459
pharmacology & pharmacy (454) 454
anticoagulants - administration & dosage (407) 407
anticoagulants (405) 405
anticoagulants - therapeutic use (399) 399
apixaban (376) 376
warfarin (355) 355
pyrazoles - adverse effects (343) 343
pyridones - pharmacokinetics (333) 333
atrial fibrillation - drug therapy (329) 329
hematology (322) 322
anticoagulants - adverse effects (315) 315
stroke - prevention & control (300) 300
dose-response relationship, drug (285) 285
rats (281) 281
atrial fibrillation (275) 275
mice (257) 257
deferiprone (254) 254
hemorrhage - chemically induced (248) 248
adolescent (242) 242
drug therapy (240) 240
beta-alanine - analogs & derivatives (237) 237
atrial fibrillation - complications (235) 235
medicine, general & internal (234) 234
aged, 80 and over (232) 232
cardiac & cardiovascular systems (232) 232
safety (227) 227
drug therapy, combination (226) 226
care and treatment (224) 224
stroke (223) 223
iron chelating agents - therapeutic use (219) 219
abridged index medicus (217) 217
risk factors (212) 212
therapy (208) 208
morpholines - therapeutic use (205) 205
milrinone (204) 204
prevention (195) 195
oncology (194) 194
analysis (190) 190
thiophenes - therapeutic use (190) 190
benzimidazoles - therapeutic use (188) 188
efficacy (187) 187
pharmacokinetics (186) 186
venous thromboembolism (185) 185
warfarin - therapeutic use (185) 185
time factors (184) 184
iron chelating agents - administration & dosage (178) 178
research (174) 174
rivaroxaban - administration & dosage (173) 173
drug administration schedule (166) 166
pirfenidone (165) 165
morpholines - administration & dosage (161) 161
peripheral vascular disease (160) 160
dabigatran - administration & dosage (159) 159
young adult (159) 159
rivaroxaban - therapeutic use (158) 158
clinical trials (157) 157
dosage and administration (156) 156
pyridones - chemistry (156) 156
imidazoles - administration & dosage (152) 152
stroke - etiology (149) 149
atrial-fibrillation (148) 148
beta-alanine - therapeutic use (148) 148
deferoxamine - therapeutic use (146) 146
double-blind method (146) 146
pyrimidinones - administration & dosage (146) 146
randomized controlled trials as topic (146) 146
retrospective studies (146) 146
thromboembolism (146) 146
benzimidazoles - administration & dosage (145) 145
factor xa inhibitors - administration & dosage (144) 144
thiophenes - administration & dosage (143) 143
double-blind (141) 141
warfarin - administration & dosage (135) 135
deferoxamine (134) 134
dabigatran - therapeutic use (133) 133
management (133) 133
child (132) 132
clinical trials as topic (132) 132
factor xa inhibitors (132) 132
warfarin - adverse effects (132) 132
cancer (131) 131
iron overload - drug therapy (131) 131
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2689) 2689
German (64) 64
Japanese (31) 31
French (28) 28
Spanish (20) 20
Italian (16) 16
Russian (10) 10
Czech (6) 6
Chinese (5) 5
Hungarian (4) 4
Swedish (4) 4
Danish (3) 3
Polish (3) 3
Norwegian (2) 2
Dutch (1) 1
Finnish (1) 1
Portuguese (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2014, Volume 64, Issue 11, pp. 1128 - 1139
Abstract Background Non–vitamin K oral anticoagulants (NOACs) do not require routine laboratory monitoring. However, laboratory measurement may be desirable in... 
Cardiovascular | Internal Medicine | dabigatran | rivaroxaban | monitoring | laboratory | apixaban | MEASURING RIVAROXABAN | CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT THROMBIN INHIBITOR | DABIGATRAN CONCENTRATIONS | PROTHROMBIN TIME | PARTIAL THROMBOPLASTIN TIME | COAGULATION ASSAYS | IN-VITRO | FACTOR-XA INHIBITOR | PLASMA-CONCENTRATIONS | INTERNATIONAL NORMALIZED RATIO | Anticoagulants - administration & dosage | Humans | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Factor Xa Inhibitors - administration & dosage | Antithrombins - pharmacology | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - pharmacology | Factor Xa Inhibitors - pharmacology | beta-Alanine - analogs & derivatives | Pyrazoles - pharmacology | Administration, Oral | Morpholines - administration & dosage | beta-Alanine - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Pyrazoles - administration & dosage | Partial Thromboplastin Time | Anticoagulants - pharmacology | Benzimidazoles - pharmacology | Drug Monitoring | Pyridones - pharmacology | Measurement | Anticoagulants (Medicine) | Vitamins | Studies | Anticoagulants | Plasma | Bibliographic literature | Laboratories | Drug therapy | Drug dosages | Bone surgery
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 03/2014, Volume 12, Issue 3, pp. 320 - 328
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
European Heart Journal, ISSN 0195-668X, 02/2013, Volume 34, Issue 7, pp. 489 - 500
Novel oral anticoagulants that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are currently available for prevention of venous... 
Novel oral anticoagulants | Bleeding | Management | RECOMBINANT FACTOR-VIIA | CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT THROMBIN INHIBITOR | RANDOMIZED EVALUATION | INTRACRANIAL HEMORRHAGE | ACTIVATED FACTOR-VII | FACTOR-XA INHIBITOR | DABIGATRAN ETEXILATE | VENOUS THROMBOEMBOLISM | PROTHROMBIN COMPLEX CONCENTRATE | NONVALVULAR ATRIAL-FIBRILLATION | Plasma | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Antithrombins - administration & dosage | Hemorrhage - prevention & control | Thiophenes - administration & dosage | Dabigatran | Antithrombins - pharmacology | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | beta-Alanine - pharmacology | Renal Insufficiency - complications | Benzimidazoles - adverse effects | Drug Therapy, Combination | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Acute Disease | beta-Alanine - adverse effects | Administration, Oral | Morpholines - administration & dosage | Risk Factors | beta-Alanine - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Anticoagulants - adverse effects | Pyrazoles - administration & dosage | Anticoagulants - pharmacology | Antithrombins - adverse effects | Blood Coagulation Tests | Benzimidazoles - pharmacology | Aged | Hemostatics - therapeutic use | Pyridones - adverse effects | Pyridones - pharmacology | Renal Dialysis
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
Stroke, ISSN 0039-2499, 06/2013, Volume 44, Issue 6, pp. 1676 - 1681
Background and Purpose-To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral... 
Intracranial hemorrhage | Stroke | Anticoagulation | Markov model | Cost-effectiveness | Atrial fibrillation | cost-effectiveness | ANTICOAGULATION CONTROL | QUALITY | anticoagulation | stroke | ASPIRIN | CLINICAL NEUROLOGY | PROPHYLAXIS | atrial fibrillation | HEART-DISEASE | BENEFIT | THERAPY | intracranial hemorrhage | SCORES | PERIPHERAL VASCULAR DISEASE | UPDATE | UTILITY | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | United States | Humans | Anticoagulants - economics | Thiophenes - administration & dosage | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - economics | Stroke - epidemiology | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Administration, Oral | Morpholines - administration & dosage | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Pyrazoles - economics | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Cohort Studies
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 06/2016, Volume 5, Issue 6, p. n/a
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2014, Volume 111, Issue 5, pp. 981 - 988
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2012, Volume 60, Issue 8, pp. 738 - 746
Objectives This study sought to perform an indirect comparison analysis of dabigatran etexilate (2 doses), rivaroxaban, and apixaban for their relative... 
Cardiovascular | Internal Medicine | indirect comparisons | dabigatran | atrial fibrillation | rivaroxaban | apixaban | stroke prevention | NETWORK | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | METAANALYSIS | RISK | THERAPY | WARFARIN | ASSOCIATION | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Dabigatran | Pyridones - administration & dosage | Rivaroxaban | Clinical Trials, Phase III as Topic | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Female | Benzimidazoles - adverse effects | Odds Ratio | Morpholines - adverse effects | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Pyrazoles - adverse effects | Pyridines - therapeutic use | Stroke - prevention & control | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Pyrazoles - administration & dosage | Stroke - etiology | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Stroke (Disease) | Usage | Analysis | Atrial fibrillation | Anticoagulants (Medicine) | Universities and colleges | Cardiology | Anticoagulants | Cardiac arrhythmia | Stroke | Drug therapy
Journal Article